{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-044830","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.922475+00:00","generated_at":"2026-05-25T13:54:20.144577+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CalciMedica reports 62.7% relative mortality reduction with Auxora in AKI subset of CARDEA trial","bullets":["In patients with AKI (eGFR ≤60) plus respiratory failure, Auxora reduced day-30 mortality by 62.7% vs placebo; 17.4% vs 46.7% died.","Absolute mortality reduction of 29.3% in AKI subset; full study showed 56.3% relative reduction (p=0.017) with 9.9% absolute reduction.","Preclinical and biomarker data supporting CRAC channel inhibition in AKI were also presented.","Ongoing Phase 2 KOURAGE trial in Stage 2/3 AKI with hypoxemic respiratory failure is expected to read out in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-044830","json":"https://secwatch.observer/filing/0001193125-25-044830.json","markdown":"https://secwatch.observer/filing/0001193125-25-044830.md","text":"https://secwatch.observer/filing/0001193125-25-044830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312525044830/0001193125-25-044830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312525044830/d824505d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T13:54:20.144577+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}